Shrapnel nanoparticles loading docetaxel inhibit metastasis and growth of breast cancer

Biomaterials

Volumn 64, Issue , 2015, Pages 10-20

  Xu, Pengfei ^a   Meng, Qingshuo ^a   Sun, Huiping ^a,b   Yin, Qi ^a   Yu, Haijun ^a   Zhang, Zhiwen ^a   Cao, Mi ^c   Zhang, Yingyi ^c   Li, Yaping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Breast cancer; Enzyme sensitive; Metastasis; Nanoparticles; Reduction sensitive; Shrapnel

Indexed keywords

ALIPHATIC COMPOUNDS; BIOLOGICAL ORGANS; BIOSYNTHESIS; CELL DEATH; CONTROLLED DRUG DELIVERY; DISEASES; DRUG PRODUCTS; ENZYMES; LIPOSOMES; MAMMALS; MICELLES; NANOPARTICLES; PARTICLE SIZE; PEPTIDES; POLYETHYLENE GLYCOLS; POLYETHYLENES; TARGETED DRUG DELIVERY; TUMORS;

AVERAGE PARTICLE SIZE; BREAST CANCER; ENCAPSULATION EFFICIENCY; MATRIX METALLOPROTEINASES; METASTASIS; METHOXYPOLYETHYLENE GLYCOL; SHRAPNEL; TUMOR MICROENVIRONMENT;

PATHOLOGY;

ALPHA TOCOPHEROL SUCCINATE; COPOLYMER; DOCETAXEL; GELATINASE B; LIPOSOME; MACROGOL DERIVATIVE; METHOXYPOLYETHYLENE GLYCOL; NANOPARTICLE; POLYPEPTIDE; SHRAPNEL NANOPARTICLE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; MICELLE; PHOSPHATIDYLCHOLINE; TAXOID; TOCOPHEROL; TUMOR PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; IC50; INTERNALIZATION; LIPOSOMAL DELIVERY; LUNG METASTASIS; METASTASIS INHIBITION; MICELLE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REDUCTION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMICAL STRUCTURE; DRUG EFFECTS; DRUG SCREENING; LUNG NEOPLASMS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; SECONDARY; SPRAGUE DAWLEY RAT; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG COMPOUNDING; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; LIPOSOMES; LUNG NEOPLASMS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; MOLECULAR STRUCTURE; NANOPARTICLES; NEOPLASM PROTEINS; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; POLYETHYLENE GLYCOLS; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; TAXOIDS; TISSUE DISTRIBUTION; TOCOPHEROLS; TUMOR MICROENVIRONMENT;

EID: 84937430411     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.06.017     Document Type: Article

References (47)

1. Jemal A., Center M.M., DeSantis C., Ward E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev. 2010, 19:1893-1907.
2. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3:453-458.
3. Bonapace L., Coissieux M.M., Wyckoff J., Mertz K.D., Varga Z., Junt T., et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 2014, 515:130-133.
4. Aceto N., Bardia A., Miyamoto D.T., Donaldson M.C., Wittner B.S., Spencer J.A., et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014, 158:1110-1122.
5. Yap T.A., Workman P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu. Rev. Pharmacol. Toxicol. 2012, 52:549-573.
6. Eckhardt B.L., Francis P.A., Parker B.S., Anderson R.L. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat. Rev. Drug Discov. 2012, 11:479-497.
7. Wang W., Ma Y., Li J., Shi H.S., Wang L.Q., Guo F.C., et al. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. Gene Ther. 2013, 20:970-978.
8. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009, 15:220-231.
9. Chen Y., Xu P., Chen H., Li Y., Bu W., Shu Z., et al. Colloidal HPMO nanoparticles: silica-etching chemistry tailoring, topological transformation, and nano-biomedical applications. Adv. Mater. 2013, 25:3100-3105.
10. Chen Y., Gu H., Zhang D.S., Li F., Liu T., Xia W. Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier. Biomaterials 2014, 35:10058-10069.
11. Chen Y., Meng Q., Wu M., Wang S., Xu P., Chen H., et al. Hollow mesoporous organosilica nanoparticles: a generic intelligent framework-hybridization approach for biomedicine. J.Am. Chem. Soc. 2014, 136:16326-16334.
12. Ortega R.A., Barham W.J., Kumar B., Tikhomirov O., McFadden I.D., Yull F.E., et al. Biocompatible mannosylated endosomal-escape nanoparticles enhance selective delivery of short nucleotide sequences to tumor associated macrophages. Nanoscale 2015, 7:500-510.
13. Yoo S.S., Razzak R., Bedard E., Guo L., Shaw A.R., Moore R.B., et al. Layered gadolinium-based nanoparticle as a novel delivery platform for microRNA therapeutics. Nanotechnology 2014, 25:425102.
14. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J.Control. Release 2000, 65:271-284.
15. Hartmann L.C., Keeney G.L., Lingle W.L., Christianson T.J.H., Varghese B., Hillman D., et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int. J. Cancer 2007, 121:938-942.
16. Bae Y.H. Drug targeting and tumor heterogeneity. J.Control. Release 2009, 133:2-3.
17. Gao G.H., Park M.J., Li Y., Im G.H., Kim J.H., Kim H.N., et al. The use of pH-sensitive positively charged polymeric micelles for protein delivery. Biomaterials 2012, 33:9157-9164.
18. Du J.Z., Du X.J., Mao C.Q., Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J.Am. Chem. Soc. 2011, 133:17560-17563.
19. Ling D., Xia H., Park W., Hackett M.J., Song C., Na K., et al. pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. ACS Nano 2014, 8:8027-8039.
20. Mok H., Lee S.H., Park J.W., Park T.G. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat. Mater. 2010, 9:272-278.
21. Li J., Huo M., Wang J., Zhou J., Mohammad J.M., Zhang Y., et al. Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials 2012, 33:2310-2320.
22. Suma T., Miyata K., Anraku Y., Watanabe S., Christie R.J., Takemoto H., et al. Smart multilayered assembly for biocompatible siRNA delivery featuring dissolvable silica, endosome-disrupting polycation, and detachable PEG. ACS Nano 2012, 6:6693-6705.
23. Dorresteijn R., Billecke N., Schwendy M., Pütz S., Bonn M., Parekh S.H., et al. Polylactide-block-polypeptide-block-polylactide copolymer nanoparticles with tunable cleavage and controlled drug release. Adv. Funct. Mater. 2014, 24:4026-4033.
24. Zhu L., Kate P., Torchilin V.P. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano 2012, 6:3491-3498.
25. Basel M.T., Shrestha T.B., Troyer D.L., Bossmann S.H. Protease-sensitive, polymer-caged liposomes: a method for making highly targeted liposomes using triggered release. ACS Nano 2011, 5:2162-2175.
26. Kuppusamy P., Li H., Ilangovan G., Cardounel A.J., Zweier J.L., Yamada K., et al. Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res. 2002, 62:307-312.
27. Schafer F.Q., Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 2001, 30:1191-1212.
28. Xu P., Yu H., Zhang Z., Meng Q., Sun H., Chen X., et al. Hydrogen-bonded and reduction-responsive micelles loading atorvastatin for therapy of breast cancer metastasis. Biomaterials 2014, 35:7574-7587.
29. Hoffman A.S. Stimuli-responsive polymers: biomedical applications and challenges for clinical translation. Adv. Drug Deliv. Rev. 2013, 65:10-16.
30. Olson E.S., Jiang T., Aguilera T.A., Nguyen Q.T., Ellies L.G., Scadeng M., et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for invivo fluorescence and MR imaging of proteases. Proc. Natl. Acad. Sci. U S A 2010, 107:4311-4316.
31. Huang Y., Jiang Y., Wang H., Wang J., Shin M.C., Byun Y., et al. Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv. Drug Deliv. Rev. 2013, 65:1299-1315.
32. Hatakeyama H., Akita H., Kogure K., Oishi M., Nagasaki Y., Kihira Y., et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 2007, 14:68-77.
33. Zhang P., Cheetham A.G., Lin Y.A., Cui H. Self-assembled Tat nanofibers as effective drug carrier and transporter. ACS Nano 2013, 7:5965-5977.
34. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 2011, 6:815-823.
35. Lee H., Fonge H., Hoang B., Reilly R.M., Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol. Pharm. 2010, 7:1195-1208.
36. Marino N., Marshall J.C., Collins J.W., Zhou M., Qian Y., Veenstra T., et al. Nm23-h1 binds to gelsolin and inactivates its actin-severing capacity to promote tumor cell motility and metastasis. Cancer Res. 2013, 73:5949-5962.
37. Li M., Tang Z., Zhang D., Sun H., Liu H., Zhang Y., et al. Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models. Biomaterials 2015, 51:161-172.
38. Yamashita F., Hashida M. Pharmacokinetic considerations for targeted drug delivery. Adv. Drug Deliv. Rev. 2013, 65:139-147.
39. Ernsting M.J., Tang W.L., MacCallum N.W., Li S.D. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials 2012, 33:1445-1454.
40. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 2008, 5:496-504.
41. Ernsting M.J., Murakami M., Roy A., Li S.D. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J.Control. Release 2013, 172:782-794.
42. Wolchok J.D., Hoos A., O'Day S., Weber J.S., Hamid O., Lebbe C., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 2009, 15:7412-7420.
43. Koontongkaew S. The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J.Cancer 2013, 4:66-83.
44. Tang L., Han X. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed. Pharmacother. 2013, 67:179-182.
45. Kunigal S., Lakka S.S., Good C.S., Estes N., Rao J.S. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int. J. Cancer 2007, 121:2307-2316.
46. Xin X., Majumder M., Girish G.V., Mohindra V., Maruyama T., Lala P.K. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab. Invest 2012, 92:1115-1128.
47. Na Y.R., Yoon Y.N., Son D.I., Seok S.H. Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS One 2013, 8:e63451.